
Copyright © 1982 BMJ Publishing Group

http://eprints.gla.ac.uk/95541/

Deposited on: 30 July 2014
Molluscum contagiosum: an unusual complication of tattooing

Molluscum contagiosum is a common viral disease of the skin. The causative virus, from its size, shape, fine structure, cytoplasmic site of replication, and characteristic inclusion body, appears to be a member of the pox group. Transmission is thought to occur by direct contact, though the incubation period is not known and inoculation experiments have failed. Although any infective condition might theoretically be inoculated by tattooing, in practice the only diseases that have been reported are pyogenic infection, syphilis, tuberculosis, serum hepatitis, and one case of viral warts.1

Case report

A 20-year-old man presented in September 1981. Seven months earlier he had had a tattoo professionally performed on his left upper arm with a single needle, using carbon, scarlet lake, and chlorinated copper pigments. Within three months of the tattooing a crop of seven lesions of molluscum contagiosum localised to the area of tattoo performed with carbon pigment had appeared. These had persisted until the time of consultation (figure). Direct microscopy of an unstained cutured lesion on a slide confirmed the diagnosis of molluscum contagiosum. A similar tattoo performed professionally on his right upper arm three years earlier had had no sequelae. He had had no other serious illnesses or skin diseases in the past apart from four common warts present on the palm of his right hand for four years. There was no family history of atopic disease. No treatment was given, and the lesions disappeared spontaneously within six months.

Comment

In this patient the virions of molluscum contagiosum were presumably inoculated at the time of tattooing and must have been present within the tattoo pigment, which consisted of charcoal suspended in ammonical solution containing phenol. To date no similar cases have been reported, which suggests that a particular host environment is required to establish the growth of molluscum contagiosum.

There is some clinical evidence that molluscum contagiosum is spread by direct contact. Seven patients under the care of one surgeon were infected with molluscum contagiosum at the site of operation.2 Three women attending a Turkish bath in Sheffield recently developed multiple lesions of molluscum contagiosum at the sites where common salt was rubbed in, suggesting that the salt contained the virus particles (unpublished observation). There have been few reports of molluscum contagiosum affecting more than one member of a family,3 however, again suggesting that a particular host environment is required. Molluscum contagiosum is thought to occur more commonly in atopic people, though there are only isolated case reports to confirm this and there is dispute over whether the lesions of molluscum contagiosum affect involved or uninvolved areas of active atopic dermatitis.4

This isolated appearance of molluscum contagiosum occurring as a result of professional tattooing, localised to one pigment of the tattoo, warrants further investigation into the host environment required for the establishment of this virus.

2 Paton EP. Seven cases in which operation wounds were infected with molluscum contagiosum. Westminster Hospital Report 1969;18:11-5.
Double-blind controlled study of primidone in essential tremor: preliminary results

Essential tremor is a common, monosymptomatic disorder for which no predictable and completely satisfactory drug treatment is available. Primidone, a well-established anticonvulsant, has been reported to be highly effective, but this has been based on only uncontrolled clinical observations. We report the preliminary results of a double-blind placebo-controlled study of primidone in essential tremor obtained using an objective recording technique.

Patients, methods, and results

We studied 11 patients with moderate to severe essential tremor aged 15-82 (mean 57) years. Mean duration of symptomatic tremor was 10.6 (range 4-24) years. The patients were not taking any other medication. Primidone and placebo were given in randomised order, according to a cross-over design, for five weeks each. Two patients received both primidone and placebo for two weeks only. Primidone was started at 62.5 mg daily and increased by 62.5 mg every day up to a maximum of 250 mg three times a day.

At the end of each five-week regimen tremor was assessed under standardised conditions by using piezoresistive linear accelerometers (ENDEVCO 7265/10) attached at the dorsum of each hand, which were maintained outstretched and pronated with the arms supported to the wrists. Derived signals were computed off-line using a spectrum analyser, as described. Measurements were taken as the root mean square magnitude of acceleration and frequency (Hz) of the dominant peak(s) in the spectrum. The unit of acceleration was referred to earth’s gravity (g = 981 cm/s²). Only data derived from the hand that was more severely affected while placebo was being taken were used for statistical analysis. When the recordings of tremor had been completed blood samples were taken for assay of serum primidone and phenobarbitone concentrations. Statistical analysis of the data was performed using Wilcoxon’s test for paired differences.

The frequency of the dominant peak of the tremor of the more affected hand ranged between 4.6 and 8.15 Hz (median 5.95 Hz) and the magnitude from 11.02 to 675.29 mg (median 30.55 mg). When the difference in magnitude was calculated as the absolute change value primidone was significantly superior to placebo (p < 0.01). In 10 patients the magnitude of tremor was lower when they received primidone compared with placebo (figure). The median reduction of the magnitude produced by primidone was 65.99% of the placebo value (range 12.7-98.1%); p < 0.01). No significant difference in the frequency of tremor was evident during primidone and placebo treatments.

Owing to dose-related side effects only seven patients achieved the maximum permitted dosage of primidone. The mean daily dosage for the whole group was 590 (range 125-750) mg daily. Serum concentrations of phenobarbitone ranged between 5 and 87 μmol/l (median 44 μmol/l) and of primidone between 18 and 100 μmol/l (median 49 μmol/l). Side effects occurred with primidone in six patients and consisted of a variable combination of sedation, tiredness, nausea, and giddiness; these were attenuated with self-resolution of dosage. In two patients, who were severely affected, tremor was reduced by more than 90% of control values to within the range of physiological tremor (figure). These patients did not experience any side effects while taking the maximum doses of primidone.

Subsequently 10 patients were put on maintenance treatment with primidone and followed up for a minimum of six months while taking the drug. All maintained satisfactory improvement.

Effect of primidone on magnitude of hand tremor in 11 patients with essential tremor (figures are root mean squares).

Comment

Our results support the findings of others that primidone consistently improves essential tremor and may be of value in long-term symptomatic control of this condition. It may represent an alternative to propranolol, hitherto the drug of choice in this disorder, particularly in patients in whom beta-adrenoceptor-blocking drugs are contraindicated.

A previous study failed to show any significant effect of phenylethylmalonamide, a major metabolite of primidone, in essential tremor; it remains to be established, therefore, whether the tremolatory effect of primidone is mediated by the parent drug itself or by derived phenobarbitone, or both.

Further studies are under way to determine whether a range of plasma concentrations of primidone or derived phenobarbitone may be established correlating with clinical effect.

References


(Received 28 May 1982)